BOTHELL, Wash., Nov. 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK), a leader in developing therapeutics using advanced molecular biology-based drug delivery technologies, announced today that it has been selected for addition to the NASDAQ Biotechnology Index(R) (NASDAQ:NBI) effective Monday, November 21, 2005. All securities in the Index are listed on the NASDAQ National Market and must meet certain eligibility criteria, including market value, average daily share volume and seasoning as a public company. "Nastech's addition to the NASDAQ Biotechnology Index reflects both the value of our clinical programs and our strong financial and operational performance," stated Phil Ranker, Chief Financial Officer of Nastech. "Inclusion in the index will enhance our visibility among the investment community as we continue to develop innovative technologies and therapeutics." Launched in 1993, the NASDAQ Biotechnology Index includes securities that are classified according to the FTSE Global Classification System(TM) as biotechnology or pharmaceutical, and is ranked on a semi-annual basis in May and November. The Index is the basis for the iShares Nasdaq Biotechnology Index(SM) (AMEX:IBB), which seeks results that generally correspond to the price and yield performance of the NASDAQ Biotechnology Index before fees and expenses. About Nastech We are a pharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. We and our collaboration partners are developing products for multiple therapeutic areas including inflammatory conditions, obesity and osteoporosis. Additional information about Nastech is available at http://www.nastech.com/. Nastech Forward Looking Statements Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events. CONTACTS: Nastech Ed Bell Senior Investor Relations Manager (425) 908-3639 Noonan Russo Matthew Haines (Investors/Media) (212) 845-4235 DATASOURCE: Nastech Pharmaceutical Company Inc. CONTACT: Ed Bell, Senior Investor Relations Manager of Nastech, +1-425-908-3639, ; or Matthew Haines, Investors/Media, of Noonan Russo for Nastech, +1-212-845-4235 Web site: http://www.nastech.com/

Copyright